Key Takeaways
- Shares of Amylyx rose approximately 21% during pre-market hours following positive Phase 3 data showing avexitide, a GLP-1 receptor antagonist, achieved all primary and secondary study goals
- Participants in the study experienced 55% fewer instances of severe low blood sugar episodes versus those receiving placebo
- Investment firm Mizuho increased its AMLX price objective from $24 to $30 while maintaining an Outperform stance
- The compound has received both FDA Breakthrough Therapy Designation and Orphan Drug Designation status
- Management is targeting a 2027 market introduction, with preliminary NDA submission work now in progress
Shares of Amylyx Pharmaceuticals experienced a significant rally of approximately 21% during Tuesday’s pre-market session following the biotechnology company’s disclosure that avexitide, an experimental GLP-1 receptor antagonist candidate, demonstrated success in its pivotal-stage clinical study. Trading reached $26.76 before regular hours, surpassing the previous 52-week peak of $24.60.
Amylyx Pharmaceuticals, Inc., AMLX
The pivotal LUCIDITY Phase 3 study consisted of a 16-week, multi-site, randomized, double-blinded, placebo-controlled investigation that recruited 78 participants. The trial evaluated avexitide’s effectiveness in treating post-bariatric hypoglycemia, a medical condition characterized by hazardous blood glucose declines following food intake, typically emerging years following bariatric surgical procedures.
The study successfully achieved its predetermined primary goal, which had received prior regulatory concurrence. Participants administered avexitide experienced a 55% reduction in severe hypoglycemic episodes relative to the control group receiving placebo.
Additionally, the investigational therapy met all predetermined secondary measures. These positive outcomes encompassed data from patient-conducted fingerstick blood glucose measurements as well as continuous glucose monitoring technology.
Avexitide operates through a distinct mechanism compared to popular GLP-1 medications such as Wegovy and Zepbound. Instead of imitating the GLP-1 hormone to reduce blood glucose levels, it antagonizes GLP-1 receptors located on pancreatic tissue, preventing excessive hormonal signaling following food consumption.
Analyst Upgrades Price Forecast
Investment banking firm Mizuho elevated its AMLX price objective to $30 from a previous $24 before the data release, while reaffirming its Outperform recommendation. The analysts also designated the stock among their preferred 2026 selections and projected a potential upward movement of $10 to $15 from preceding price levels contingent on favorable Phase 3 outcomes.
The therapeutic candidate has secured both FDA Breakthrough Therapy Designation as well as Orphan Drug Designation, regulatory classifications that may facilitate an expedited approval timeline.
Company representatives disclosed that preliminary work toward New Drug Application submission readiness has commenced. Management anticipates a potential commercial introduction during 2027.
Broader Market Environment
The positive stock movement occurred against a challenging backdrop for equity markets overall. The Nasdaq Composite declined 1.2% while the S&P 500 index retreated 0.5% during pre-market activity. The biotechnology sector similarly confronted selling pressure throughout the session.
Company leadership conducted an executive management investor call at 8:00 a.m. Eastern Time on Tuesday to elaborate on the clinical trial outcomes.
Management had originally communicated expectations for a third quarter 2026 timeframe for the data disclosure. Tuesday’s release significantly accelerated that projected timeline.
The pre-market trading price of $26.76 for AMLX shares represented a substantial advance beyond the stock’s prior 52-week maximum of $24.60.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
